What is Opus Genetics ROE % Adjusted to Book Value?
Opus Genetics's ROE % for the quarter that ended in Dec. 2024 was -685.16%. Opus Genetics's PB Ratio for the quarter that ended in Dec. 2024 was 5.59.
Opus Genetics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -122.57%.
Opus Genetics ROE % Adjusted to Book Value Historical Data
The historical data trend for Opus Genetics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Opus Genetics's ROE % Adjusted to Book Value
For the Biotechnology subindustry, Opus Genetics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Opus Genetics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of Opus Genetics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IRD has been successfully added to your 